BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Breaking News: Try BioWorld for free for two weeks
See today's BioWorld Science
Home
» Targeting PFKFB3 as a potential strategy in infantile hemangioma treatment
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Neonatal/Pediatrics
Targeting PFKFB3 as a potential strategy in infantile hemangioma treatment
Feb. 14, 2023
No Comments
Infantile hemangioma (IH) is the most common benign vascular tumor seen in childhood. After an early proliferative phase in the first weeks of life, the majority of hemangiomas complete their growth and start to involute by approximately 12 months.
BioWorld Science
Dermatologic
Neonatal/pediatrics